<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1918">
  <stage>Registered</stage>
  <submitdate>9/04/2008</submitdate>
  <approvaldate>9/04/2008</approvaldate>
  <nctid>NCT00658086</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)</studytitle>
    <scientifictitle>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALN-RSV01-106</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory Syncytial Virus Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ALN-RSV01
Treatment: drugs - normal saline

Active Comparator: 1 - ALN-RSV01

Placebo Comparator: 2 - Normal saline


Treatment: drugs: ALN-RSV01
administered by nebulization once daily for 3 days

Treatment: drugs: normal saline
administered by nebulization once daily for 3 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess safety and tolerability of aerosolized ALN-RSV01 versus placebo in lung transplant patients infected with RSV</outcome>
      <timepoint>Day 30</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate effects of ALN-RSV01 on clinical and virologic endpoints</outcome>
      <timepoint>Throughout Trial</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Single or bilateral lung transplant recipients

          -  Confirmed RSV infection

          -  Greater than 90 days post current lung transplant

          -  Rejection free for a minimum of 1 month</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection
             at the time of diagnosis

          -  Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has
             not been stable for at least 3 months

          -  Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or
             thymoglobulin within 3 months of screening: concurrent use of &gt;= 0.3 mg/kg/day
             prednisone or equivalent as maintenance therapy

          -  active treament for acute graft rejection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA</recruitmentstate>
    <hospital>Clinical Site - Sydney</hospital>
    <hospital>Clinical Site - Brisbane</hospital>
    <hospital>Clinical Site - Perth</hospital>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alnylam Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected
      lung transplant patients</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00658086</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin Zamora, MD</name>
      <address>University of Colorado Health Science Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>